Polycystic ovary syndrome and ovulation induction

Obstetrics and Gynecology Clinics of North America

Volumn 28, Issue 1, 2001, Pages 165-182

  Phipps, W R ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE CITRATE; GONADOTROPIN; METFORMIN;

ARTICLE; DRUG EFFECT; DRUG MECHANISM; ENZYME DEFICIENCY; HUMAN; OBESITY; OUTCOMES RESEARCH; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; WEIGHT REDUCTION;

EID: 0035081340     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(05)70192-3     Document Type: Article

References (98)

1. Multifetal pregnancies: Epidemiology, clinical characteristics, and management
2. Clomiphene citrate: The case for a monoisomeric preparation
3. Ovulation induction: Clomiphene citrate
4. Managing the anovulatory state: Medical induction of ovulation
5. Time interval from human chorionic gonadotrophin (HCG) injection to follicular rupture
6. Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: A prospective study
7. Metformin
8. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism
9. Exogenous estrogen therapy for treatment of clomiphene citrate-induced cervical mucus abnormalities: Is it effective?
10. Multiple gestation: Incidence, etiology, and inheritance
11. Hypothalamic-pituitary-adrenocortical function during long-term low-dose dexamethasone therapy in hyperandrogenized women
12. Treatment of chronic anovulation resistant to clomiphene citrate (CC) by using oral contraceptive ovarian suppression followed by repeat CC treatment
13. A double blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovary syndrome
14. Ovulatory cycles, pregnancy outcome and complications after surgical treatment of polycystic ovary syndrome
15. Prolactin secretion in polycystic ovary syndrome (PCO): Correlation with the steroid pattern
16. Diagnosis of polycystic ovary syndrome
17. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women
18. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment
19. The agonistic-antagonistic properties of clomiphene: A review
20. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: A prospective, multicenter, assessor-blind, randomized, clinical trial
21. Clomiphene citrate: Nuances of clinical application
22. Determinants of ovarian cancer risk. I. Reproductive experiences and family history
23. Teratogenic effects of clomiphene, tamoxifen, and diethylstilbestrol on the developing human female genital tract
24. A randomized study of dexamethasone in ovulation induction with clomiphene citrate
25. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome
26. Risk of ovarian cancer after treatment for infertility
27. Increased monozygotic twinning rate after ovulation induction
28. Clinical and biological phenotypes in late-onset 21-hydroxylase deficiency
29. Relationship of endometrial thickness and pattern to fecundity in ovulation induction cycles: Effect of clomiphene citrate alone and with human menopausal gonadotropin
30. Relationship of follicle number and other factors to fecundability and multiple pregnancy in clomiphene citrate-induced intrauterine insemination cycles
31. The effect of leuprolide acetate on ovulation induction with human menopausal gonadotropins in polycystic ovary syndrome
32. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
33. Insulin-lowering therapeutic modalities for polycystic ovary syndrome
34. Effect of laparoscopic ovarian electrocautery on ovarian response and outcome of treatment with gonadotropins in clomiphene citrate-resistant patients with polycystic ovary syndrome
35. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding
36. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH
37. Ovulation induction: Gonadotropins
38. The response of patients with polycystic ovarian disease to human menopausal gonadotropin therapy after ovarian electrocautery or a luteinizing hormone-releasing hormone agonist
39. The effect of clomiphene citrate and menopausal gonadotropins on cervical mucus in ovulatory cycles
40. Use of ethinyl estradiol to reverse the antiestrogenic effects of clomiphene citrate in patients undergoing intrauterine insemination: A comparative, randomized study
41. Composition of commercial gonadotrophin preparations extracted from human postmenopausal urine: Characterization of nongonadotrophin proteins
42. Clomiphene citrate
43. A comparison of the effects on follicular development between clomiphene citrate, its two separate isomers and spontaneous cycles
44. Adhesion formation after laparoscopic ovarian cautery for polycystic ovarian syndrome: Lack of correlation with pregnancy rate
45. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women
46. A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test
47. Low-dose gonadotropin therapy for induction of ovulation in 100 women with polycystic ovary syndrome
48. Weight loss is associated with correction of gonadotropin and sex steroid abnormalities in the obese anovulatory female
49. Effects of weight loss on the hormonal profile in obese, infertile women
50. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: Rationale, results, reflections and refinements
51. Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome
52. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: Role of insulin sensitivity and luteinizing hormone
53. Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called "hyperthecosis"
54. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility
55. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
56. Extended clomiphene citrate (CC) prednisone for the treatment of chronic anovulation resistant to CC alone
57. The use of cortisone in follicular phase disturbances
58. Pathophysiology of reproductive failure after clomiphene-induced ovulation
59. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome
60. Insulin sensitizers and polycystic ovary syndrome: Can a diabetes medication treat infertility?
61. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome
62. Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels
63. The role of the adrenal in polycystic ovarian syndrome
64. An extended regimen of clomiphene citrate in women unresponsive to standard therapy
65. Hyperprolactinemia in polycystic ovary syndrome
66. Ovulation induction: Step-up and step-down regimens
67. Polycystic ovarian disease and dexamethasone
68. Editorial comment: "the Clomid twins" waiting for single isomer heaven
69. Clinical and biochemical evaluation of Cushing's syndrome
70. Low dose follicle-stimulating hormone therapy for polycystic ovarian disease
71. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers
72. High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome
73. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
74. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
75. Adhesion formation after laparoscopic electrocoagulation of the ovarian surface in polycystic ovary patients
76. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens
77. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome
78. Ovulatory and metabolic effects of D-chiroinositol in the polycystic ovary syndrome
79. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss
80. Disorders of the adrenal cortex
81. Physiology and tests of adrenal cortical function
82. Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization
83. Sensitivity of cortisol and adrenal androgens to dexamethasone suppression in hirsute women
84. Ovarian tumors in a cohort of infertile women
85. A comparative, randomized study of low-dose human menopausal gonadotropin and follicle-stimulating hormone in women with polycystic ovarian syndrome
86. Relationship of weight to successful induction of ovulation with clomiphene citrate
87. Polycystic ovarian syndrome: Safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone
88. The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovarian disease
89. Ovarian drilling
90. A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome
91. Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: Prospective, randomized comparison between low dose step-up and step-down dose regimens
92. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
93. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women
94. The induction of ovulation by tamoxifen
95. Chronic anovulation caused by peripheral endocrine disorders
96. Polycystic ovary syndrome hyperandrogenic chronic anovulation
97. Hyperprolactinemia and polycystic ovarian syndrome
98. Polycystic ovary syndrome